Saphris Coupon

Claim your free Asenapine discount card

We offer free Saphris coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Asenapine every time. What are you waiting for? Claim your prescription drug card now!

Asenapine volume of distribution

Asenapine is rapidly distributed and has a large volume of distribution (approximately 20 – 25 L/kg), indicating extensive extravascular distribution.

What is Asenapine

Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009.

Asenapine mechanism of action

Asenapine is an atypical antipsychotic multireceptor neuroleptic drug which shows strong 5HT2A (serotonin) and D2 (dopamine) receptor antagonism, which has been shown to enhance dopamine (DA) and acetylcholine (Ach) efflux in rat brains. Asenapine may improve cognitive function and negative symptoms in patients with schizophrenia.

Dosage forms of Asenapine

Indication of Asenapine

Used for treatment in psychosis, schizophrenia and schizoaffective disorders, manic disorders, and bipolar disorders as monotherapy or in combination.

Toxicity of Asenapine

In patients with schizophrenia, asenapine (in sublingual dosages of 5, 10, 15, or 20 mg twice daily) was associated with relatively small increases in the corrected QT (QTc) interval of 2-5 msec compared with placebo in a controlled and dedicated QT study; these increases were slightly lower than those observed in patients receiving quetiapine. None of the asenapine-treated patients in this study experienced a QTc-interval prolongation of 60 msec or greater compared with baseline, nor did any patient experience a QTc interval of 500 msec or greater. During short-term clinical trials in patients receiving 5 or 10 mg of asenapine sublingually twice daily, post-baseline QT-interval prolongation exceeding 500 msec was reported at similar rates for asenapine and placebo.